List of Excipients in Branded Drug TARPEYO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Calliditas Therapeutics AB	TARPEYO	budesonide	81749-004	CITRIC ACID MONOHYDRATE
Calliditas Therapeutics AB	TARPEYO	budesonide	81749-004	DIBUTYL SEBACATE
Calliditas Therapeutics AB	TARPEYO	budesonide	81749-004	ETHYLCELLULOSE
Calliditas Therapeutics AB	TARPEYO	budesonide	81749-004	FERROSOFERRIC OXIDE
Calliditas Therapeutics AB	TARPEYO	budesonide	81749-004	HYPROMELLOSE

TARPEYO Excipient Strategy, Formulation IP and Commercial Opportunities

Last updated: August 2, 2026

TARPEYO is a 4-mg delayed-release budesonide capsule developed by Calliditas Therapeutics for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression. Its commercial value depends on targeted ileal delivery, chronic oral dosing, manufacturing reliability and patent protection around the formulation and method of use. The strongest excipient opportunity is not a new inactive ingredient. It is supply, coating-process control, capsule manufacturing and development of equivalent delayed-release systems for generic or follow-on products.

TARPEYO received accelerated FDA approval in December 2021 and traditional approval in December 2023 after confirmatory clinical data supported reduced loss of kidney function. Asahi Kasei acquired Calliditas in 2024, making TARPEYO part of Asahi Kasei's renal specialty portfolio.[1-3]

What excipients are used in TARPEYO capsules?

TARPEYO uses a multiparticulate delayed-release system. Budesonide is loaded onto or incorporated into small pharmaceutical cores and protected with polymeric coating layers designed to limit release in the stomach and proximal small intestine. The formulation is intended to release budesonide in the ileum, near the site of mucosal immune activity implicated in IgA nephropathy.

FDA labeling identifies excipient categories associated with the capsule, drug-loaded cores and enteric-release coating. The principal formulation components include:

Formulation function	TARPEYO excipient or material category	Commercial role
Core or pellet support	Sugar spheres	Provides uniform multiparticulate cores
Binder	Povidone	Promotes adhesion of budesonide to cores
Sustained-release or barrier layer	Ethylcellulose	Controls diffusion and protects drug layers
Enteric coating	Methacrylic acid copolymer	Delays release at gastric pH
Coating plasticizer	Triethyl citrate or related citrate plasticizer	Reduces coating brittleness
Anti-tacking and process aid	Talc	Supports coating uniformity
Surfactant	Polysorbate 80	Improves wetting and coating dispersion
Capsule shell	Hypromellose or gelatin-based capsule materials	Provides oral dosage form and identification
Colorants and opacifiers	Titanium dioxide and approved colorants	Supports product identification and light protection

The exact commercial specification for each material, including grade, particle-size distribution, residual solvents and microbial limits, is part of the controlled manufacturing process rather than simply the public ingredient list. The FDA prescribing information is the primary public source for the listed inactive ingredients.[1]

How does TARPEYO’s delayed-release excipient system work?

TARPEYO’s commercial differentiation comes from site-specific release rather than from systemic budesonide exposure alone.

The formulation strategy has four technical requirements:

1. It must remain substantially intact during gastric transit.
2. It must tolerate changing pH through the upper gastrointestinal tract.
3. It must release budesonide reproducibly in the ileal region.
4. It must maintain dose uniformity across a multiparticulate capsule.

Methacrylic acid copolymer is central to the enteric function. Its ionization at higher intestinal pH allows the coating to dissolve after gastric passage. Ethylcellulose or a similar barrier material can moderate water penetration and drug diffusion. Plasticizers such as triethyl citrate improve film flexibility during coating, drying, packaging and storage.

This architecture creates manufacturing barriers that are more significant than the simple use of budesonide. A conventional immediate-release budesonide capsule would not necessarily reproduce TARPEYO’s local exposure profile or clinical performance.

Which excipient attributes matter most?

The most commercially important attributes are:

• Polymer grade and acid dissolution profile
• Coating weight gain
• Pellet size distribution
• Budesonide loading uniformity
• Residual solvent levels
• Plasticizer concentration
• Coating adhesion and friability
• Moisture uptake
• Capsule fill-weight variation
• Dissolution performance across multiple pH stages

A generic developer may be able to substitute excipients, but it must demonstrate equivalent release behavior and product performance. In practice, excipient substitution can create regulatory risk if the substitute changes dissolution, stability, local exposure or pharmacokinetics.

What commercial opportunities exist in TARPEYO excipients?

The largest opportunities are in excipient supply and specialized manufacturing rather than in selling an unbranded inactive ingredient.

Enteric polymer supply

Methacrylic acid copolymers are available from multiple established suppliers. A supplier that can provide consistent pharmaceutical-grade material, technical support and validated global supply has an opportunity to enter the TARPEYO ecosystem through contract manufacturers or future generic applicants.

The key selling points are:

• Consistent dissolution at the target pH
• Low lot-to-lot variability
• Global regulatory documentation
• Reliable supply of aqueous or organic dispersions
• Support for continuous or high-throughput coating
• Compatibility with budesonide and other corticosteroids

The opportunity is competitive because enteric polymers are generally nonproprietary and have multiple commercial sources.

Pellet and multiparticulate manufacturing

TARPEYO-type products require equipment and know-how for fluid-bed coating, layering, drying and capsule filling. Contract development and manufacturing organizations with multiparticulate capabilities can compete for:

• Generic TARPEYO development
• Regional versions of budesonide delayed-release products
• Lifecycle-management products
• Clinical-stage ileal-delivery drugs
• Reformulations using smaller capsules or alternative strengths

Process control is a stronger barrier than excipient ownership. A manufacturer with validated coating equipment and dissolution expertise may have more value than a supplier with a standard polymer catalogue.

Excipient substitution and dual sourcing

A second-source strategy can reduce dependence on one polymer, plasticizer or capsule supplier. The most attractive targets are materials with:

• Established pharmacopeial status
• Broad FDA or European regulatory history
• Comparable particle size and viscosity
• Existing drug-master-file support
• Demonstrated enteric dissolution performance

The substitution must preserve the finished product’s critical quality attributes. A lower-cost excipient is commercially useful only if it avoids a major reformulation or bridging burden.

New dosage forms

Potential lifecycle products include:

• Lower-strength capsules for dose titration
• Higher-strength capsules to reduce pill burden
• Sprinkle or sachet formulations for patients with swallowing difficulty
• Modified capsule shells
• Combination products for IgA nephropathy
• Pediatric or adolescent formulations, subject to clinical and regulatory support
• Alternative ileal-release budesonide products

Each product would face a balance between clinical value, additional development cost and the remaining patent term.

What patents protect TARPEYO?

TARPEYO’s protection is expected to rest on several patent categories:

Protection category	Likely subject matter	Relevance
Composition and formulation	Budesonide multiparticulate or delayed-release dosage form	Protects the product architecture
Site-specific delivery	Release in the ileum or distal small intestine	Supports product differentiation
Method of treatment	Treatment of primary IgA nephropathy with targeted-release budesonide	Can delay generic commercial entry
Manufacturing	Layering, coating, drying or pellet production	May restrict manufacturing routes
Clinical use	Patient selection, dosing and disease-progression risk	May support method-of-use litigation

The relevant patent estate should be reviewed in the FDA Orange Book, USPTO records and litigation dockets. Patent expiration dates can differ because of patent-term adjustment, patent-term extension, terminal disclaimers and claim-specific outcomes. The earliest unexpired formulation patent, rather than the latest published patent number, usually drives the practical entry analysis.[4,5]

How strong is the TARPEYO patent estate?

The estate is stronger where claims cover the commercial product’s essential release profile and clinical use. It is weaker where claims depend on narrow excipient identities that can be designed around.

The strongest claim types are likely to be:

• Claims tied to a defined ileal-release profile
• Claims covering the full multiparticulate architecture
• Method claims directed to IgA nephropathy
• Claims supported by clinical evidence showing reduced kidney-function decline

Potential design-around routes include:

• A different enteric polymer
• A different pellet core
• A different coating sequence
• A different release pH
• An alternative dosage form
• A non-infringing method-of-use label

A design-around that changes the excipient but reproduces the claimed release mechanism may not avoid infringement. Conversely, a product with a different release location may face clinical-development requirements that reduce its commercial attractiveness.

What is the Orange Book status of TARPEYO?

TARPEYO is an FDA-approved prescription drug subject to Orange Book patent and exclusivity analysis. The product is a delayed-release oral capsule containing budesonide. Its regulatory pathway is an abbreviated new drug application, or ANDA, for future generic applicants rather than a biosimilar pathway.

The key Orange Book issues are:

• Listed patents covering the formulation and method of use
• Remaining FDA exclusivity
• Paragraph IV certifications
• Potential 30-month litigation stays
• Whether a generic applicant can obtain approval for all or only part of the indication
• Whether a method-of-use patent can be carved out of the generic label

TARPEYO’s FDA exclusivity position changed materially when the product moved from accelerated approval to traditional approval in December 2023. The approval conversion strengthened the commercial basis for a long-term IgA nephropathy franchise, but patent expiry remains the principal entry variable.[1,4]

When does TARPEYO lose exclusivity?

TARPEYO’s market exclusivity does not end on one universal date. FDA regulatory exclusivity and patent exclusivity operate separately.

Exclusivity type	TARPEYO relevance
New chemical entity exclusivity	Generally not available because budesonide was previously approved
Orphan-drug exclusivity	IgA nephropathy status must be assessed separately from standard product exclusivity
Accelerated-approval period	Applied before conversion to traditional approval
Patent protection	Depends on listed formulation and method-of-use patents
Pediatric exclusivity	Applies only if FDA grants the six-month extension
Litigation stay	May delay ANDA approval after a timely Paragraph IV suit

Budesonide itself is an old active ingredient. The commercial protection therefore depends heavily on formulation, use and regulatory barriers rather than molecule-level exclusivity.

Which companies are challenging TARPEYO?

A future generic challenge would most likely come from companies with established oral solid-dose, multiparticulate or modified-release capabilities. Potential participants in this product class include large generic manufacturers and specialty pharmaceutical companies with renal portfolios.

A Paragraph IV applicant could challenge:

• The validity of formulation claims
• The enforceability of listed patents
• Infringement under a proposed generic process
• The scope of method-of-use claims
• The adequacy of patent listing in the Orange Book

A first filer may obtain 180-day generic exclusivity if statutory requirements are satisfied. The value of that position depends on whether the applicant can manufacture a product with equivalent dissolution and obtain approval without an injunction or settlement restriction.

No biosimilar pathway applies. TARPEYO is a small-molecule budesonide product, so competitive entry would occur through the ANDA pathway.

What patent litigation affects TARPEYO?

The central litigation risk is an ANDA Paragraph IV case. Such a case would likely focus on whether a proposed product reproduces the claimed delayed-release system or falls within method-of-use claims for IgA nephropathy.

The most important litigation questions would be:

1. Whether the relevant claims require specific excipients or only functional release characteristics.
2. Whether a generic’s alternative polymer avoids literal infringement.
3. Whether the doctrine of equivalents applies to a substituted coating system.
4. Whether method-of-use claims can be carved out through a skinny label.
5. Whether the patent claims are enabled and adequately supported by the specification.
6. Whether the patent was properly listed in the Orange Book.

Settlement agreements could permit a generic launch before patent expiry, subject to confidential commercial terms, authorized-generic arrangements or restrictions on the approved indication. The commercial value of settlement depends on launch timing, first-filer status and the ability to promote the IgA nephropathy indication.

How does TARPEYO compare with competing IgA nephropathy therapies?

TARPEYO occupies a targeted-release corticosteroid position. It competes with systemic immunosuppression, optimized supportive care and newer targeted therapies.

Product or approach	Active mechanism	Delivery strategy	Competitive effect
TARPEYO	Ileal-targeted budesonide	Delayed-release oral capsule	Directly targets mucosal immune biology
Nefecon-type products	Targeted-release budesonide	Similar ileal-release concept	Potential formulation and market comparison
Sparsentan	Endothelin and angiotensin pathway inhibition	Immediate-release oral therapy	Competes for kidney-protection prescribing
Supportive care	Renin-angiotensin system control and risk reduction	Conventional oral treatment	Lower-cost baseline therapy
SGLT2 inhibitors	Renal and hemodynamic effects	Oral tablets	Expands treatment alternatives

Nefecon is the development name associated with the targeted-release budesonide technology underlying TARPEYO. The commercial distinction is therefore based on regulatory approval, label scope, clinical evidence, access and patent position rather than on budesonide as a new molecule.[2,6]

What generic entry risks exist for TARPEYO?

The principal entry risks are:

• A generic applicant replicating the release profile with non-identical excipients
• A successful Paragraph IV challenge
• A narrow method-of-use carve-out that still permits effective substitution
• Patent invalidity or non-infringement findings
• Loss of prescriber preference after lower-cost alternatives emerge
• Payer pressure before patent expiry
• Manufacturing failures involving enteric coating or capsule supply
• Regulatory acceptance of an alternative multiparticulate system

The most defensible commercial position is a product with multiple independent claim categories supported by clinical and dissolution data. A narrow claim covering one polymer or one plasticizer is easier to design around than a claim covering the overall release architecture and therapeutic use.

What geographic opportunities exist for TARPEYO excipients and follow-on products?

The United States is the primary commercial market because FDA approval established the first major targeted-release budesonide opportunity for IgA nephropathy. Europe and other markets may offer opportunities for:

• Regional licensing
• Local manufacturing
• Excipient supply agreements
• Technology-transfer partnerships
• Generic development after patent expiry
• Use of the platform in other immune-mediated kidney diseases

Geographic freedom to operate must be assessed separately. A patent that expires or is unenforceable in one country may remain active elsewhere. Regulatory requirements also differ for modified-release equivalence, clinical bridging and medical-use claims.

What licensing deals affect TARPEYO?

Calliditas licensed or developed the Nefecon technology before commercializing TARPEYO, and Asahi Kasei acquired Calliditas in 2024. The acquisition transferred control of TARPEYO and the related renal pipeline to Asahi Kasei.[2,3]

For excipient and manufacturing companies, the relevant licensing opportunities are likely to involve:

• Enteric polymer supply
• Contract development and manufacturing
• Regional commercialization
• Generic or authorized-generic rights
• New indications using targeted-release budesonide
• Platform licensing for ileal delivery

The most valuable deal structure would combine formulation know-how, manufacturing rights and territory-specific regulatory rights. A simple excipient supply agreement would carry lower strategic value unless it includes preferred-supplier status or technical exclusivity.

Key Takeaways

• TARPEYO’s commercial differentiation comes from ileal-targeted delayed release, not from novel budesonide.
• The core excipient opportunity is in enteric polymers, pellet production, coating technology and supply-chain qualification.
• Generic developers can potentially design around individual excipients, but they must reproduce the required release and product-performance profile.
• TARPEYO is subject to small-molecule ANDA competition, not biosimilar competition.
• FDA exclusivity is distinct from patent protection and should be analyzed separately.
• Method-of-use, formulation and manufacturing patents may create different litigation and design-around risks.
• Asahi Kasei’s 2024 acquisition of Calliditas consolidated control of TARPEYO and its related technology.
• The strongest follow-on opportunities are specialized contract manufacturing, regional licensing and alternative delayed-release budesonide products.

FAQs About TARPEYO Excipients and Commercial Strategy

Can a generic TARPEYO use different excipients?

Yes. An ANDA applicant may use different excipients if the finished product satisfies applicable pharmaceutical equivalence, bioequivalence, quality and dissolution requirements and does not infringe enforceable patent claims.

Is TARPEYO an enteric-coated capsule?

Yes. TARPEYO uses delayed-release multiparticulates designed to protect budesonide during gastric transit and release it in the intestinal region associated with the ileum.

Does TARPEYO have biosimilar competition?

No. Budesonide is a small molecule. Competing products would generally use the ANDA generic-drug pathway rather than the biosimilar pathway.

What is the most difficult manufacturing step for TARPEYO-type products?

Uniform multiparticulate coating is likely the main technical challenge. Pellet size, coating weight, polymer performance, drying conditions and dissolution control must remain within tight specifications.

Can TARPEYO be reformulated with a new capsule or stronger dose?

Potentially, but a new strength or dosage form would require regulatory development and may require additional clinical, bioequivalence or usability evidence. Patent and exclusivity consequences would depend on the specific product and claims.

References

1. U.S. Food and Drug Administration. (2023). TARPEYO (budesonide) delayed-release capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2023, December 20). FDA grants traditional approval for targeted-release budesonide for IgA nephropathy.
3. Asahi Kasei Corporation. (2024). Acquisition of Calliditas Therapeutics AB.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources.
6. Fellström, B., Barratt, J., Cook, H., et al. (2021). Targeted-release budesonide versus placebo in patients with IgA nephropathy. The Lancet, 398(10302), 1575-1585.